Jonathan Zalevsky
Senior VP and Chief Research & Development OfficerDr. Jonathan Zalevsky, Ph.D. has been Senior Vice President and Chief Research & Development Officer at Nektar Therapeutics since October 2019. He has also served as a director of InveniAI since 2017, of AlphaMeld Corporation since December 2024. Dr. Zalevsky served as Senior Vice President, Biology and Preclinical Development from April 2017 through November 2017. Dr. Zalevsky serves as Independent Director at Invea Therapeutics, Inc. since November 2021. Dr. Zalevsky served as Director at ReAlta Life Sciences Inc. November 2019 to December 2023. Dr. Zalevsky served as Chief Scientific Officer at Nektar Therapeutics since November 22, 2017 until October 2019. He was Senior Vice President of Research at Nektar Therapeutics since November 22, 2017 and its Vice President of Biology & Preclinical Development since July 2015 until November 22, 2017. Dr. Zalevsky joined Nektar in July 2015 to lead biological research and grow the discovery portfolio. He has lots of experience spanning both large pharmaceutical and small biotechnology companies. He served as the Global Vice President and Head of the Inflammation Drug Discovery Unit at Takeda Pharmaceuticals. He served as Global Head of Immunology and Vice President of Process Science at Takeda California, Inc. As the leading immunologist for Takeda, he was responsible for an immunology pipeline that spanned from early target discovery to late-stage development and launched products. While at Takeda, Dr. Zalevsky's leadership resulted in a few new INDs and Phase 1 clinical starts, which included both internally-discovered and in-licensed first-in-class immune-targeting molecules. Prior to joining Takeda in 2009, Dr. Zalevsky held a number of research and development positions at Xencor, Inc. where he was responsible for the discovery and development of Xencor's first few clinical-stage assets. During that period, he authored numerous high-profile publications on Xencor-discovered drugs and wrote four INDs. Dr. Zalevsky served as a Member of Advisory Board at BioMotiv, LLC. In his career, he worked as a Developmental Biologist at Stanford University. Dr. Zalevsky received his Ph.D. in Biochemistry and Biophysics from the Tetrad Program at the University of California at San Francisco (UCSF). He earned his Bachelor of Arts in Biochemistry and Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder.
Positions
- Company NameNektar TherapeuticsStock CodeNKTRPositionSenior VP and Chief Research & Development OfficerColleagues
- HWHoward W. RobinCEO, President & Director
- RBRobert B. ChessIndependent Chairman of the Board
- LMLinda M. RubinsteinCFO and Principal Financial & Accounting Officer
- JBJason BarnardChief Accounting Officer
- EZElizabeth ZhangVP of Legal, Corporate Counsel & Secretary
- RARoy A. WhitfieldLead Independent Director
- RSR. Scott GreerIndependent Director
- DMDiana M. BrainardIndependent Director
